Clinical Trial Finder

Inclusion Criteria:

• - Written informed consent and HIPAA authorization (applies to covered entities in the USA only) obtained from the subject/legal representative prior to performing any protocol-related procedures, including screening evaluations.

• - Age ≥18 years old at the time of screening.

• - Histologically confirmed diagnosis of World Health Organization Grade IV malignant glioma (glioblastoma or gliosarcoma) - Previous first line treatment with radiotherapy and temozolomide (treatment prior to radiation and temozolomide permitted, [ie, Gliadel]) - Documented first recurrence of GBM by diagnostic biopsy or by contrast-enhanced magnetic resonance imaging (MRI) as per Updated Response Assessment Criteria of High Grade Gliomas- Neuro-Oncology Working Group (Wen et al, 2010) - Life expectancy ≥ 12 weeks.

• - Adequate hematologic and organ function.

• - Negative serum pregnancy test (women only) - Two methods of birth control for female participants of child-bearing potential or male participants with their female partners of child-bearing potential.

Exclusion Criteria:

• - Treatment with any chemotherapy, radiotherapy, immunotherapy, biologic, hormonal therapy or investigational agent 30 days prior to study entry.

• - Concurrent enrollment in another clinical study involving an investigational agent.

• - Employees of the clinical study site or any other individuals involved with the conduct of the study, or immediate family members of such individuals.

• - Previous mAb treatment specifically directed against PDGF or PDGF receptors.

• - Previous bevacizumab or other VEGF and anti-angiogenic treatment.

• - More than 1 recurrence of GBM.

• - Any surgery (not including minor diagnostic procedures) within 2 weeks prior to baseline disease assessments; or not fully recovered from any side effects of previous procedures.

• - History of serious allergy or reaction to any component of the MEDI-575 formulation.

• - New York Heart Association ≥ Grade 2 congestive heart failure within 6 months prior to study entry.

• - Uncontrolled or significant cardiovascular disease.

• - History of other invasive malignancy within 5 years prior to study entry except for cervical carcinoma in situ (CIS), non-melanomatous carcinoma of the skin or ductal carcinoma in situ (DCIS) of the breast that have been surgically cured.

• - History of active human immunodeficiency virus or active hepatitis B or C viral infection will be excluded to eliminate the risk of increased AEs due to immune compromise.

• - Systemic immunosuppressive therapy.

- Subjects taking corticosteroids must be on a stable dose for 7 days prior to initiation of treatment with MEDI-575 16) Presence of extracranial metastatic or leptomeningeal disease

This is a Phase 2, multicenter, open-label, single-arm study to evaluate the antitumor activity, safety, and pharmacology of MEDI-575 in adult subjects with first recurrence of GBM. Approximately 55 subjects will be enrolled to determine the preliminary efficacy profile of MEDI-575 in the treatment of subjects with first recurrence of GBM. Subjects will receive MEDI-575 as a 60-minute IV infusion on Day 1 every 21 days until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, or other reasons for subject withdrawal. The primary assessment of antitumor activity is PFS-6; tumor response and progression will be determined using Updated Response Assessment Criteria of High Grade Gliomas- Neuro-Oncology Working Group v.1. Approximately 15 investigational sites in the United States will participate in this study. All subjects will be followed every 3 months for the duration of the trial (defined as 9 months from the date the last subject is entered into the trial or when the sponsor stops the study.

Arms

Experimental: MEDI-575, 25 mg/kg

MEDI-575 administered as an intravenous infusion at 25 mg/kg over a period of 60-minutes on Day 1 of each 21-day cycle until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, or other reasons for participants withdrawal.

Interventions

Drug: - MEDI-575

MEDI-575 as an IV infusion.